Możliwości zastosowania kwasu liponowego w terapii niektórych chorób

• Autorzy: Wojcik M. , Litwinczuk Z.

Warianty tytułu

EN

Possibilities of use of lipoic acid in the treatment of certain diseases

• Języki publikacji: PL

Abstrakty

PL

W artykule przedstawiono przegląd schorzeń, w których stosuje się kwas liponowy (ALA) jako środek leczniczy lub wspomagający terapię. Właściwości anty oksydacyjne liponianu decydują o jego szerokim spektrum działania w stosunku do chorób, w których czynnikiem etiologicznym jest stres oksydacyjny. Kwas liponowy znajduje zastosowanie w profilaktyce i leczeniu cukrzycy oraz jej powikłań - neuropatii cukrzycowej. Ponadto dobre skutki terapeutyczne przynosi podawanie liponianu przy wirusowym zapaleniu wątroby oraz zatruciach powodowanych metalami ciężkimi. Zapobiegawczo ALA stosuje się, aby zmniejszyć straty masy kostnej; w przypadku otyłości, uszkodzeń spojówki i rogówki oka. Immunomodulujące właściwości kwasu liponowego wskazują na jego skuteczność w terapii stwardnienia rozsianego i astmy. Przedstawiona szeroka gama korzyści wynikających ze stosowania liponianu, w połączeniu z jego doskonałą tolerancją przez organizm oraz bardzo dobrą przyswajalnością, decydują o jego rosnącej popularności wśród substancji o działaniu antyoksydacyjnym, a zarazem terapeutycznym.

EN

Current article presents an overview of diseases in which the lipoic acid (ALA) can be used as a therapeutic agent or assist the therapy. Antioxidant properties of lipoic acid determine its broad spectrum of efficiency against various diseases, in which an oxidative stress is considered to be the etiologie factor. Lipoic acid is used to prevent and treat diabetes and complications liable to occur, for example diabetic neuropathy. Furthermore, administration of lipoic acid has a good therapeutic impact on viral hepatitis and heavy metal poisoning. ALA can be also used preventively to reduce the bone mass loss in conditions such as obesity, conjunctiva and cornea injuries. Immunomodulatory influence of lipoic acid indicates the efficiency in the treatments for multiple sclerosis and asthma, including limitation of the oncological changes and decrease of the negative effects of chemotherapy. Wide range of presented beneficial uses of lipoic acid together with its excellent tolerance by the body and good bioavailability decide about ALA's growing importance among the substances with antioxidative properties associated with the therapeutical effect.

Słowa kluczowe

PL

choroby czlowieka; leczenie; kwas liponowy; przeciwutleniacze; stres oksydacyjny; cukrzyca

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2010
• Tom: 37
• Numer: 2
• Opis fizyczny: s.98-104,bibliogr.

Twórcy

autor

Wojcik M.

• Wydział Biologii i Hodowli Zwierząt, Uniwersytet Przyrodniczy w Lublinie, Lublin

autor

Litwinczuk Z.

Bibliografia

• 1. Ziegler D.: Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab. Res. Rev., 2008, 24, 52-7.
• 2. Singh U., Jialal I.: Alpha-lipoic acid supplementation and diabetes. Nutr. Rev., 2008, 66, 11, 646-57.
• 3. Burekovic A., Terzić M., Alajbegovic S., et al.: The role of alpha-lipoic acid in diabetic polyneuropathy treatment. Bosn. J. Basic Med. Sci., 2008, 8, 4, 341-5.
• 4. Varko- nyi T., Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes. Metab., 2008, 10, 2, 99-108.
• 5. Foster T.S.: Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Educ., 2007, 33, 1, 111-7.
• 6. Bloch-Damti A., Bashan N.: Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid. Redox. Signal., 2005, 7, 11-12, 1553-67.
• 7. Vincent A.M., McLean L.L., Backus C., et al.: Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J., 2005, 19, 6, 638-40.
• 8. Huang E.A, Gitelman S.E.: The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatr. Diabetes., 2008, 9, 69-73.
• 9. Gonzalez-Perez O., Moy-López N.A., Guzman- Muńiz J.: Alpha-tocopherol and alpha-lipoic acid. An antioxidant synergy with potential for preventive medicine. Rev. Invest. Clin., 2008, 60, 1, 58-67.
• 10. Obrosova I.G., Fathallah L., Liu E., et al.: Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid. Free Radie. Biol. Med., 2003, 34, 2, 186-95.
• 11. Lateef H., Aslam M.N., Stevens M.J., et al.: Pretreatment of diabetic rats with lipoic acid improves healing of subsequently-induced abrasion wounds. Arch. Dermatol. Res., 2005, 297, 2, 75-83.
• 12. Alieva R., Nasole E., Di Donato E, et al.: Alpha-Lipoic acid supplementation inhibits oxidative damage, accelerating chronic wound healing in patients undergoing hyperbaric oxygen therapy. Biochem. Bio- phys. Res. Commun., 2005, 29, 333, 2, 404-10.
• 13. Jacob S., Ruus E, Hermann R., et al.: Oral administration of RAC-alpha- lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radie. Biol. Med., 1999, 27, 309-314.
• 14. Henriksen E.J.: Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radie. Biol. Med., 2006, 40, 1, 3-12.
• 15. Henriksen E.J., Saeng- sirisuwan V: Exercise training and antioxidants: relief from oxidative stress and insulin resistance. Exerc. Sport Sci. Rev., 2003, 31, 2, 79-84.
• 16. Thirunavukka- rasu V, Anitha Nandhini A.T., Anuradha C.V: Lipoic acid improves glucose utilisation and prevents protein glycation and AGE formation. Pharmazie., 2005, 60, 10, 772-5.
• 17. Thirunavukkarasu V, Anuradha C.V: Influence of alpha-lipoic acid on lipid peroxidation and antioxidant defence system in blood of insulin-resistant rats. Diabetes Obes. Metab., 2004, 6, 3, 200-7.
• 18. Melhem A., Stern M., Shibolet O. et al.: Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J. Clin. Gastroenterol., 2005, 39, 8, 737-42.
• 19. Suntres Z.E.: Prophylaxis against lipopolysaccharide-induced liver injuries by lipoic acid in rats. Pharmacol. Res., 2003, 48, 6, 585-91.
• 20. Malińska D., Winiarska K.: Lipoic acid: characteristics and therapeutic application. Postępy Hig. Med. Doiw., 2005, 59, 535-43.
• 21. Selvakumar E., Prahalathan C., Mythili Y., et al.: Mitigation of oxidative stress in cyclophosphamide-challenged hepatic tissue by DL-alpha-lipoic acid. Mol. Cell. Biochem., 2005, 272, 1-2, 179-85.
• 22. Pari L., Murugavel P: Protective effect of alpha-lipoic acid against chloroquine-induced hepatotoxicity in rats. J. Appl. Toxicol., 2004, 24, 1, 21-6.
• 23. Savitha S., Sivarajan K., Haripriya D., et al.: Efficacy of levo carnitine and alpha lipoic acid in ameliorating the decline in mitochondrial enzymes during aging. Clin. Nutr., 2005, 24, 5, 794-800.
• 24. Savitha S., Ta- milselvan J., Anusuyadevi M., et al.: Oxidative stress on mitochondrial antioxidant defense system in the aging process: role of DL-alpha-lipoic acid and L-carnitine. Clin. Chim. Acta 2005, 355, 1-2, 173-80.
• 25. Valko M., Rhodes C.J., Moncol J., et al.: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact., 2006, 160, 1, 1-40.
• 26. Balachandar A.V, Malarkodi K.P, Varalak- shmi P: Protective role of DLalpha-lipoic acid against adriamycin-induced cardiac lipid peroxidation. Hum. Exp. Toxicol., 2003, 22, 5, 249-54.
• 27. Malarkodi K.P, Balachandar A.V., Varlakshmi R: The influence of lipoic acid on adriamycin-induced hyperlipidémie nephrotoxicity in rats. Mol. Cell. Biochem., 2003, 247, 1-2, 139-45.
• 28. Byun C.H., Koh J.M., Kim D.K., et al.: Alpha-lipoic acid inhibits TNF- alpha-induced apoptosis in human bone marrow stromal cells. J. Bone Miner. Res., 2005, 20, 7, 1125-35.
• 29. Demir U., Demir T, Ilhan N.: The protective effect of alpha-lipoic acid against oxidative damage in rabbit conjunctiva and cornea exposed to ultraviolet radiation. Ophthalmologica 2005, 219, 1, 49-53.
• 30. Shila S., Kokilavani V, Subathra M., et al.: Brain regional responses in antioxidant system to alpha-lipoic acid in arsenic intoxicated rat. Toxicology 2005, 210, 1, 25-36.
• 31. Shila S., Subathra M., Devi M.A., et al.: Arsenic intoxication-induced reduction of glutathione level and of the activity of related enzymes in rat brain regions: reversal by DL-alpha-lipoic acid. Arch. Toxicol., 2005, 79, 3, 140-6
• 32. Patrick L.: Toxic metals and antioxidants: Part II. The role of antioxidants in arsenic and cadmium toxicity. Altern. Med. Rev., 2003, 8, 2, 106-28.
• 33. Cho K.J., Moini H., Shon H.K., et al.: Alpha-lipoic acid decreases thiol reactivity of the insulin receptor and protein tyrosine phosphatase IB in 3T3-L1 adipocytes. Biochem. Pharmacol., 2003, 66, 5,849-58.
• 34. Lee W.J., Song K.H., Koh E.H., et al.: Apha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem. Biophys. Res. Commun., 2005, 332, 3, 885-91.
• 35. Kim M.S., Park J.Y., Namkoong C., et al.: Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med., 2004, 10, 7, 727-33.
• 36. Kiemer A.K., Muller C., Vollmar A.M.: Inhibition of LPS-induced nitric oxide and TNF-alpha production by alpha-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunol. Cell. Biol., 2002, 80, 550-557.
• 37. Morini M., Roccatagliata L., Dell’Eva R., et al.: Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2004, 148, 1- 2, 146-53.
• 38. Marracci G.H., McKeon G.P, Marquardt W.E., et al.: Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J. Neurosci. Res., 2004, 78, 3, 362-70.
• 39. Yadav V., Marracci G., Lovera J., et al.: Lipoic acid in multiple sclerosis: a pilot study. Mult. Scier., 2005, 11, 2, 159-65.
• 40. Cho Y.S., Lee J., Lee T.H., et al.: Alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Allergy Clin. Immunol., 2004, 114, 2, 429-35.